Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening – The VICTORION-PLAQUE primary prevention trial

By afschroeder • August 7, 2025

Revaiah PC, Serruys PW, Onuma Y, Andreini D, Budoff MJ, Sharif F, Chernofsky A, Vikarunnessa S, Wiethoff AJ, Yates D, Achouba A. Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening - The VICTORION-PLAQUE primary prevention trial. Am Heart J. 2025 Aug 4:S0002-8703(25)00291-1. doi: 10.1016/j.ahj.2025.08.001. Epub ahead of print. PMID: 40769373.

Tags: Cardiology/Epi, CCTA derived Fractional Flow Reserve (FFR(CT)), coronary computed tomography angiography (CCTA), CT-adapted Leaman score, Harbor UCLA, Inclisiran, Low density Lipoprotein Cholesterol (LDL-C), non-obstructive coronary artery disease (NOCAD), Publications, total atheroma volume (TAV)

Systemic Inflammation and Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease

Sandhu AT, Furst A, Rodriguez F, Kalwani N, Maron D, Nallamshetty S, Din N, Zitko K, Khachatourian K, Skaar JR, Tonnu-Mihara I. Systemic Inflammation and[...]

Breaking Barriers to Transplantation: Desensitization with Daratumumab in Peripartum Cardiomyopathy

Okwuosa I, Kumar A, Choi SM, Kamath M, Vellanki S. Breaking Barriers to Transplantation: Desensitization with Daratumumab in Peripartum Cardiomyopathy. Can J Cardiol. 2026 Apr[...]

Systems Genetics Reveals ITIH5 as a Key Mediator of Adipocyte-Endothelial Crosstalk

Zhou M, Velez LM, Kwan D, Moses L, Johnson CD, Nguyen CM, Mott L, Gamie F, Fouladi M, Bae H, Verlande A, Arneson D, Petrus[...]